Phase 1b Study of Teclistamab and Iberdomide Combination Therapy for Adults with Relapsed or Refractory Multiple Myeloma

What this Trial Is About

Researchers are evaluating the safety, side effects, and best dose of a combination treatment using iberdomide and teclistamab for adults with multiple myeloma that has returned or does not respond to treatment. Iberdomide works by targeting proteins that help cancer cells survive, while teclistamab is an immunotherapy that helps the immune system attack the cancer. This phase Ib study also explores how the combination affects the tumor environment and measures tumor response and survival outcomes. Participants receive teclistamab as a subcutaneous injection on specific days during each 28-day cycle, starting with days 1, 4, 7, 15, and 22 in the first cycle and days 1, 8, 15, and 22 in later cycles. Iberdomide is given orally once daily from days 1 to 21 starting in the second cycle. Treatment continues for up to 4 years unless the disease worsens or side effects become unacceptable. Throughout the study, patients undergo blood and urine tests, bone marrow biopsies, and imaging scans like PETCT or PETMR to monitor their condition. After completing treatment, participants are followed every 3 to 6 months for up to 2 years to observe long-term effects and disease status. Researchers assess the recommended dose level, safety, tumor response, minimal residual disease, survival, and progression-free survival. The study includes regular sample collections and imaging to understand treatment impact and disease progression over time.

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma